Headlines about Agilent Technologies (NYSE:A) have been trending somewhat positive on Friday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agilent Technologies earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 46.2827272781658 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Accern’s analysis:
- Analyzing Harvard Bioscience (HBIO) and Agilent Technologies (A) (americanbankingnews.com)
- Agilent Technologies (A) Declares $0.149 Quarterly Dividend; 1% Yield (streetinsider.com)
- Agilent Technologies and Three More Healthcare Stocks Under Our Scanner (finance.yahoo.com)
- Leerink Swann Weighs in on Agilent Technologies’ FY2018 Earnings (A) (americanbankingnews.com)
- Agilent Technologies (A) Declares $0.15 Quarterly Dividend (americanbankingnews.com)
Several research firms have weighed in on A. Goldman Sachs raised Agilent Technologies from a “neutral” rating to a “buy” rating in a research report on Monday, April 9th. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 target price for the company in a research report on Tuesday, March 27th. Morgan Stanley lowered their price target on Agilent Technologies from $95.00 to $91.00 and set an “overweight” rating for the company in a report on Wednesday, April 11th. Robert W. Baird reaffirmed a “buy” rating and issued a $76.00 target price on shares of Agilent Technologies in a report on Thursday, January 18th. Finally, ValuEngine cut Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Agilent Technologies has a consensus rating of “Buy” and a consensus target price of $72.20.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, May 14th. The medical research company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.01. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.21 billion. Agilent Technologies had a return on equity of 18.01% and a net margin of 5.02%. Agilent Technologies’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.58 EPS. equities research analysts forecast that Agilent Technologies will post 2.67 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 25th. Stockholders of record on Tuesday, July 3rd will be given a $0.149 dividend. The ex-dividend date of this dividend is Monday, July 2nd. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.93%. Agilent Technologies’s dividend payout ratio is currently 25.42%.
In other Agilent Technologies news, Director Heidi Fields sold 5,000 shares of the business’s stock in a transaction on Tuesday, March 27th. The shares were sold at an average price of $68.09, for a total transaction of $340,450.00. Following the completion of the sale, the director now directly owns 57,563 shares in the company, valued at approximately $3,919,464.67. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Patrick Kaltenbach sold 4,000 shares of the business’s stock in a transaction on Thursday, March 29th. The shares were sold at an average price of $67.28, for a total transaction of $269,120.00. Following the sale, the insider now owns 72,547 shares of the company’s stock, valued at $4,880,962.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,700 shares of company stock worth $1,586,452.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.